
OSE Immunotherapeutics SA
PAR:OSE

OSE Immunotherapeutics SA
Interest Income Expense
OSE Immunotherapeutics SA
Interest Income Expense Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Interest Income Expense | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
![]() |
OSE Immunotherapeutics SA
PAR:OSE
|
Interest Income Expense
-€5.8m
|
CAGR 3-Years
-161%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
![]() |
Valneva SE
PAR:VLA
|
Interest Income Expense
-€24.8m
|
CAGR 3-Years
-44%
|
CAGR 5-Years
-235%
|
CAGR 10-Years
-28%
|
|
![]() |
Nanobiotix SA
PAR:NANO
|
Interest Income Expense
-€10.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-20%
|
CAGR 10-Years
N/A
|
|
G
|
Genfit SA
PAR:GNFT
|
Interest Income Expense
-€2.6m
|
CAGR 3-Years
44%
|
CAGR 5-Years
29%
|
CAGR 10-Years
N/A
|
|
![]() |
Inventiva SA
PAR:IVA
|
Interest Income Expense
-€8.2m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
![]() |
Eurobio Scientific SA
PAR:ALERS
|
Interest Income Expense
-€3.4m
|
CAGR 3-Years
-68%
|
CAGR 5-Years
-32%
|
CAGR 10-Years
-29%
|
OSE Immunotherapeutics SA
Glance View
OSE Immunotherapeutics SA develops immunotherapy products for cancer and auto-immune disease. The company is headquartered in Nantes, Pays De La Loire and currently employs 61 full-time employees. The company went IPO on 2015-03-30. The company develops immunotherapies, directly or through partnerships, for the activation and regulation of the immune system in immuno-oncology and in autoimmune diseases. The firm's research and development in immunology is based on 3 platforms, such as T cell-based vaccines, Immuno-Oncology (myeloid targets) and Auto-Immunity & Inflammation. The company provides technological and scientific platforms: neoepitopes, agonist or antagonist monoclonal antibodies, ideally positioned to fight cancer and autoimmune diseases.

See Also
What is OSE Immunotherapeutics SA's Interest Income Expense?
Interest Income Expense
-5.8m
EUR
Based on the financial report for Jun 30, 2024, OSE Immunotherapeutics SA's Interest Income Expense amounts to -5.8m EUR.
What is OSE Immunotherapeutics SA's Interest Income Expense growth rate?
Interest Income Expense CAGR 3Y
-161%
The average annual Interest Income Expense growth rates for OSE Immunotherapeutics SA have been -161% over the past three years .